Themis Medicare Ltd

Themis Medicare Ltd

₹ 216 2.97%
26 Apr - close price
About

Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]

Key Points

Product Portfolio
The company manufactures and markets bulk APIs of synthetic and biotech origin, bulk intermediates, and formulations. In the formulations segment, the company manufactures anti-TB, anti-malarial, anti-cholesterol, and pain management drugs. [1]
The company manufactures 190+ different drugs for ~20 different therapeutic areas. [2]

  • Market Cap 1,992 Cr.
  • Current Price 216
  • High / Low 266 / 131
  • Stock P/E 71.9
  • Book Value 32.2
  • Dividend Yield 0.23 %
  • ROCE 19.6 %
  • ROE 16.5 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 36.0% CAGR over last 5 years

Cons

  • Debtor days have increased from 122 to 150 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
65.52 61.77 112.50 107.39 94.92 79.80 94.44 91.00 88.78 80.10 96.65 104.78 82.51
50.26 49.16 72.02 83.93 77.62 65.38 74.07 69.65 73.51 69.61 74.91 92.37 74.44
Operating Profit 15.26 12.61 40.48 23.46 17.30 14.42 20.37 21.35 15.27 10.49 21.74 12.41 8.07
OPM % 23.29% 20.41% 35.98% 21.85% 18.23% 18.07% 21.57% 23.46% 17.20% 13.10% 22.49% 11.84% 9.78%
0.25 0.88 0.35 0.21 4.14 1.84 0.68 1.97 5.90 2.95 0.65 2.44 0.56
Interest 2.92 3.09 2.67 2.05 2.13 1.93 2.26 2.37 2.23 2.71 2.49 2.04 2.68
Depreciation 2.09 2.38 2.35 2.38 2.37 2.39 2.46 2.56 2.67 2.80 3.03 3.07 3.10
Profit before tax 10.50 8.02 35.81 19.24 16.94 11.94 16.33 18.39 16.27 7.93 16.87 9.74 2.85
Tax % 19.24% 14.96% 25.33% 21.47% 28.28% 36.77% 28.72% 26.37% 25.75% 23.83% 25.61% 27.10% 29.82%
8.48 6.82 26.73 15.12 12.15 7.55 11.63 13.53 12.09 6.04 12.56 7.10 2.00
EPS in Rs 0.92 0.74 2.91 1.64 1.32 0.82 1.26 1.47 1.31 0.66 1.37 0.77 0.22
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
138 148 172 167 203 217 210 184 202 231 395 354 364
156 139 153 156 171 184 184 182 166 181 299 287 311
Operating Profit -18 9 19 11 31 33 26 3 36 50 96 67 53
OPM % -13% 6% 11% 7% 15% 15% 12% 1% 18% 22% 24% 19% 14%
2 3 4 12 3 3 3 3 3 4 7 12 7
Interest 13 15 16 14 12 12 12 12 13 13 9 10 10
Depreciation 5 6 6 7 7 7 7 8 8 9 9 10 12
Profit before tax -35 -9 1 2 15 16 9 -15 18 32 84 59 37
Tax % 0% 5% -34% -30% -4% 10% 1% 13% 12% 17% 27% 26%
-35 -8 2 2 15 15 9 -13 16 27 62 43 28
EPS in Rs -4.31 -1.01 0.18 0.24 1.77 1.64 1.01 -1.38 1.73 2.90 6.69 4.71 3.02
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 10% 15% 7% 11%
Compounded Sales Growth
10 Years: 9%
5 Years: 11%
3 Years: 21%
TTM: 3%
Compounded Profit Growth
10 Years: 22%
5 Years: 36%
3 Years: 40%
TTM: -38%
Stock Price CAGR
10 Years: 41%
5 Years: 50%
3 Years: 82%
1 Year: 38%
Return on Equity
10 Years: 13%
5 Years: 14%
3 Years: 20%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 8 8 8 8 9 9 9 9 9 9 9 9 9
Reserves 44 36 40 40 56 133 147 134 150 177 234 273 287
121 124 115 109 95 82 80 82 100 87 80 92 95
65 58 67 67 61 54 56 74 67 65 61 82 90
Total Liabilities 238 225 231 225 220 278 292 299 326 338 384 456 481
104 94 91 92 89 124 126 123 116 133 144 162 166
CWIP 7 10 11 3 5 9 2 2 8 2 3 3 3
Investments 7 10 10 11 11 12 11 11 11 11 11 11 11
120 111 119 119 115 133 153 162 191 192 226 280 301
Total Assets 238 225 231 225 220 278 292 299 326 338 384 456 481

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-14 -3 8 11 19 -2 8 11 0 57 34 16
-7 -1 -3 -2 -4 -4 -0 -4 -5 -16 -16 -24
-1 28 2 -15 -13 5 -9 -10 7 -26 -18 0
Net Cash Flow -21 24 8 -6 2 -0 -1 -3 2 16 1 -8

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 114 65 71 88 73 81 120 145 186 123 93 150
Inventory Days 150 237 231 223 210 250 253 284 313 273 150 213
Days Payable 223 247 250 272 152 163 156 186 171 144 79 123
Cash Conversion Cycle 41 55 52 38 131 168 217 243 328 253 165 239
Working Capital Days 96 77 63 68 53 74 132 134 178 154 125 177
ROCE % -12% 4% 10% 10% 17% 15% 9% -1% 13% 17% 31% 20%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
67.22% 67.18% 67.18% 67.18% 67.18% 67.17% 67.17% 67.16% 67.16% 67.16% 67.16% 67.15%
0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.06% 0.04% 0.05% 0.01% 0.03%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
32.77% 32.81% 32.81% 32.81% 32.81% 32.80% 32.78% 32.78% 32.80% 32.77% 32.82% 32.81%
No. of Shareholders 6,8226,5116,2125,8915,9156,1266,3625,9276,0076,97011,24411,295

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents